S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
pixel
Log in
OTCMKTS:CLPBY

Coloplast A/S Stock Forecast, Price & News

$14.89
+0.13 (+0.88 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.79
Now: $14.89
$14.98
50-Day Range
$14.50
MA: $15.07
$15.56
52-Week Range
$14.30
Now: $14.89
$17.80
Volume84,026 shs
Average Volume124,463 shs
Market Capitalization$32.16 billion
P/E Ratio53.18
Dividend Yield1.47%
Beta0.28
Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catheterization for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Coloplast A/S logo

MarketRank

Overall MarketRank

1.04 out of 5 stars

Medical Sector

951st out of 1,925 stocks

Surgical Appliances & Supplies Industry

22nd out of 40 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CLPBY
Previous SymbolNASDAQ:CLPBY
CUSIPN/A
CIKN/A
Phone45-4911-1111
Employees12,427

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.76 billion
Cash Flow$0.28 per share
Book Value$0.48 per share

Profitability

Net Income$585.21 million

Miscellaneous

Outstanding Shares2,160,000,000
Market Cap$32.16 billion
Next Earnings DateN/A
OptionableNot Optionable
$14.89
+0.13 (+0.88 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLPBY News and Ratings via Email

Sign-up to receive the latest news and ratings for CLPBY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Coloplast A/S (OTCMKTS:CLPBY) Frequently Asked Questions

How has Coloplast A/S's stock price been impacted by COVID-19 (Coronavirus)?

Coloplast A/S's stock was trading at $13.5590 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLPBY stock has increased by 9.8% and is now trading at $14.89.
View which stocks have been most impacted by COVID-19
.

Is Coloplast A/S a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coloplast A/S in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Coloplast A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLPBY, but not buy additional shares or sell existing shares.
View analyst ratings for Coloplast A/S
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Coloplast A/S?

Wall Street analysts have given Coloplast A/S a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Coloplast A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Coloplast A/S's earnings last quarter?

Coloplast A/S (OTCMKTS:CLPBY) announced its quarterly earnings results on Thursday, May, 2nd. The company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. The business earned $688.45 million during the quarter. Coloplast A/S had a return on equity of 69.30% and a net margin of 21.62%.
View Coloplast A/S's earnings history
.

How often does Coloplast A/S pay dividends? What is the dividend yield for Coloplast A/S?

Coloplast A/S announced a dividend on Thursday, December 3rd. Shareholders of record on Friday, January 1st will be given a dividend of $0.2791 per share on Friday, December 18th. This represents a yield of 1.86%. The ex-dividend date of this dividend is Friday, December 4th.
View Coloplast A/S's dividend history
.

Is Coloplast A/S a good dividend stock?

Coloplast A/S pays an annual dividend of $0.22 per share and currently has a dividend yield of 1.47%. The dividend payout ratio of Coloplast A/S is 73.33%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Coloplast A/S will have a dividend payout ratio of 61.11% next year. This indicates that Coloplast A/S will be able to sustain or increase its dividend.
View Coloplast A/S's dividend history.

What guidance has Coloplast A/S issued on next quarter's earnings?

Coloplast A/S updated its FY 2021 Pre-Market earnings guidance on Tuesday, November, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.891-2.919 billion.

Are investors shorting Coloplast A/S?

Coloplast A/S saw a increase in short interest in December. As of December 31st, there was short interest totaling 40,500 shares, an increase of 159.6% from the December 15th total of 15,600 shares. Based on an average daily volume of 102,800 shares, the days-to-cover ratio is currently 0.4 days.
View Coloplast A/S's Short Interest
.

Who are some of Coloplast A/S's key competitors?

Who are Coloplast A/S's key executives?

Coloplast A/S's management team includes the following people:
  • Mr. Kristian Villumsen, Pres & CEO (Age 51)
  • Mr. Anders Lonning-Skovgaard, Exec. VP & CFO (Age 49)
  • Mr. Allan Rasmussen, Exec. VP of Global Operations (Age 54)
  • Mr. Paul Marcun, Exec. VP of Growth (Age 55)
  • Mr. Thomas Barfod, Sr. Controller & Director (Age 51)
  • Ellen Bjurgert, VP of Investor Relations
  • Dennis Kaysen, Director of Corp. Communications
  • Ms. Camilla G. Mohl, Sr. VP of People & Culture
  • Mr. Nicolai Buhl Andersen, Exec. VP of Innovation
  • Mr. Alain Morvan, Sr. VP of Sales Europe

What is Coloplast A/S's stock symbol?

Coloplast A/S trades on the OTCMKTS under the ticker symbol "CLPBY."

How do I buy shares of Coloplast A/S?

Shares of CLPBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Coloplast A/S's stock price today?

One share of CLPBY stock can currently be purchased for approximately $14.89.

How big of a company is Coloplast A/S?

Coloplast A/S has a market capitalization of $32.16 billion and generates $2.76 billion in revenue each year. The company earns $585.21 million in net income (profit) each year or $0.30 on an earnings per share basis. Coloplast A/S employs 12,427 workers across the globe.

What is Coloplast A/S's official website?

The official website for Coloplast A/S is www.coloplast.com.

How can I contact Coloplast A/S?

Coloplast A/S's mailing address is HOLTEDAM 1-3, HUMLEBAEK G7, 3050. The company can be reached via phone at 45-4911-1111 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.